SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Madrigal Pharmaceuticals
An SI Board Since April 2018
Posts SubjectMarks Bans Symbol
138 9 0 MDGL
Emcee:  Lynn Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
113I'm a little concerned about the powering for the stage 2/3 cohorts now. Totuck-7/19/2019
112Could be to speed enrollment.DewDiligence_on_SI-7/19/2019
111Two new updates to the P3 clinical trial. One is a name - "MAESTRO-NASH&qutuck-7/19/2019
110<Few details were unveiled about that deal, which concerned two undisclosed tMiljenko Zuanic-7/2/2019
109B-I licenses dual-acting NASH candidate: investorshub.advfn.comDewDiligence_on_SI-7/1/2019
108A competitor with a singular focus on NASH via activation of most - but not all tuck-6/20/2019
107I poked around in the CRO's website. They have two sites in San Antonio andtuck15/21/2019
106Because of the Pinnacle Clinical Research involvement, we may not know which (hoMiljenko Zuanic-5/21/2019
105Worried? What for? Just enjoy another $60-70/share decline...(just kiding). I reMiljenko Zuanic-5/15/2019
104"An experienced group of NASH investigators and clinical sites around the wtuck-5/14/2019
103I am in Croatia, slow respond. Longer trial is must, surrogate/biopsy (samplingMiljenko Zuanic-5/3/2019
102I don't think I learned anything of consequence from reading those tweets.DewDiligence_on_SI-4/30/2019
101Interesting "tweetorial" from a nephrologist, concerning NASH trial outuck-4/30/2019
100<These big companies seem to have more disasters than successes on buyouts.&gMiljenko Zuanic-4/16/2019
99You have the MDGL/VKTX drugs. The various GILD/GNFT/NGM drugs. Now these GLP-1 dJamesK-4/16/2019
98Can not figure it out how was I fooled by the false and excessive hype of the imMiljenko Zuanic14/15/2019
97< I have significantly reduced my mdgl position simply due to all the bad macMiljenko Zuanic-4/12/2019
96Thanks for sharing your thoughts. A year ago I thought NASH market (if it achiekeokalani'nui-4/12/2019
95Will 3196 prove sufficiently strong to compete with single MoA? Possible but unlDewDiligence_on_SI-4/12/2019
94You guys all but predicted a combination including GLP-1. Nice work.DewDiligence_on_SI-4/12/2019
93GILD/NOVO going with triple (with GLP-1), while MDGL is firing away. gilead.com Miljenko Zuanic-4/12/2019
92Thanks. It is not secret that wast majority of the NASH pts are obese/pre-diabeMiljenko Zuanic-4/5/2019
91Deletedtuck-4/4/2019
90This review from 2018 suggests you are correct. ncbi.nlm.nih.gov >>No phkeokalani'nui-4/4/2019
89I don't know the reason for GLP-1 and vitamin-E exclusions. Are there any DDDewDiligence_on_SI-4/4/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News